Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Ludwig scientist Colin Goding has been awarded a £94,000 grant by the Masonic Samaritan Fund, to support a project searching for drugs that could be used in the future treat both cancer and neurodegenerative diseases. The donation was presented to Prof. Goding by James Hilditch, Provincial Grand Master for the Masonic Province of Oxfordshire, at the Old Road Campus Research Building on 15th October 2015.

msf-logo.gifThe Masonic Samaritan Fund is the Freemasons’ health and care charity and the Ludwig Institute for Cancer Research was one of 13 medical charities nominated to receive the funds in a poll of Freemasons.

colin-goding-msf-award-2015.jpegColin Goding’s project is following up on the findings that the TFEB gene affects the ability of non-melanoma cancer cells to spread throughout the body and that altering the activity of the TFEB gene can reverse symptoms of Alzheimer’s, Parkinson’s and Huntington’s diseases in mouse models of these diseases. He now plans to search through 6000 drugs already approved for clinical use to identify those that control TFEB activity. Identifying such drugs that are already being used for other purposes will enable more rapid clinical application in cancer and neurodegeneration than traditional searches for novel drugs with unknown safety records.